找回密碼
 To register

QQ登錄

只需一步,快速開(kāi)始

掃一掃,訪問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: Case-Based Gynecological Oncology; Kavita Singh,Bindiya Gupta Book 2023 The Editor(s) (if applicable) and The Author(s), under exclusive l

[復(fù)制鏈接]
樓主: 磨損
21#
發(fā)表于 2025-3-25 06:05:53 | 只看該作者
Epithelial Ovarian Cancer: High Grade SerousEpithelial ovarian cancer mainly presents in advanced stage. In recent years, treatment has been revolutionized by changes in surgical and medical management, introduction of targeted therapies and biomarker directed therapies. This change in the treatment paradigm has had substantially improved survival statistics.
22#
發(fā)表于 2025-3-25 10:39:01 | 只看該作者
Recurrent Ovarian CancerRecurrent ovarian cancer may be sensitive to platinum or platinum resistant. Management includes a combination of chemotherapy and targeted therapy. Secondary debulking surgery can be done in select cases where it is possible to achieve complete cytoreduction..This chapter will discuss clinical scenarios of recurrent ovarian cancer.
23#
發(fā)表于 2025-3-25 14:05:11 | 只看該作者
24#
發(fā)表于 2025-3-25 16:56:49 | 只看該作者
25#
發(fā)表于 2025-3-25 20:14:28 | 只看該作者
26#
發(fā)表于 2025-3-26 02:03:09 | 只看該作者
27#
發(fā)表于 2025-3-26 05:21:12 | 只看該作者
28#
發(fā)表于 2025-3-26 11:27:07 | 只看該作者
Metastatic Ovarian Canceristochemistry especially using CK7 and CK20 are the most commonly used antigens in differentiating between primary and metastatic ovarian tumours. Genetic testing is crucial for counselling and tailoring management. Treatment is mainly palliative chemotherapy while in select cases metastatectomy or cytoreductive surgery may be useful.
29#
發(fā)表于 2025-3-26 13:51:58 | 只看該作者
Borderline Ovarian Tumours: Early and Advance Stage: Serous, Mucinous, Micro Invasive Cancer, Invasi mild nuclear atypia without destructive stromal invasion. These account for 10–15% of all epithelial tumours. The most common subtypes are serous and mucinous tumours. Surgery is the mainstay of management and these are associated with better prognosis than invasive carcinomas.
30#
發(fā)表于 2025-3-26 19:31:56 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-12 18:44
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
若羌县| 海城市| 奉贤区| 玛多县| 太康县| 海城市| 北票市| 肥城市| 集安市| 昔阳县| 郎溪县| 三都| 蚌埠市| 青岛市| 东源县| 云浮市| 平舆县| 大安市| 鸡泽县| 呼伦贝尔市| 濮阳市| 化德县| 和硕县| 栾川县| 澎湖县| 山阳县| 屏东市| 松原市| 峨眉山市| 慈溪市| 海原县| 林口县| 武隆县| 新竹县| 明光市| 旌德县| 延吉市| 亚东县| 柳河县| 闽侯县| 普兰店市|